肩痛颗粒治疗肩周炎的临床观察

目的:初步观察和评价肩痛颗粒治疗肩痹(肩周炎)属风寒湿痹证者的疗效和安全性。方法:采用随机双盲、双模拟、平行阳性药对照的临床试验方法,将72例肩周炎(风寒湿痹证)患者,随机分为试验组(肩痛颗粒组)和对照组(祛痹肩安丸组),两组每次服用颗粒剂和丸剂各1袋,一日3次,疗程为4周。按照症状、体征分级量化标准,对治疗前及用药后每周进行疗效评价;并对患者进行用药前后的三大常规、心、肝、肾功能等安全性检查,观察以上安全性指标的变化。结果:疗效性结果:肩痛颗粒组的愈显率为29.63%,总有效率为92.59%;而祛痹肩安丸组分别为16.67%和83.33%。两组差别无统计学。每周证候总积分:试验组患者用药后21、28d中医证候总积分下降值和下降率均高于对照组,但差别无统计学意义。安全性结果:治疗前后患者的指标差异值无临床意义,未观察到药物引起的不良反应和不良事件。结论:肩痛颗粒在目前的口服剂量疗程范围内,治疗证属风寒湿痹的肩周炎疗效确切,安全,无毒副作用,是一种治疗肩周炎安全、有效的中药新药。     

基于"欧盟草药专论"解析中药欧盟注册关键问题

欧盟2004/24/EC法令针对传统草药药品实行简化注册程序,很大程度降低了草药药品上市门槛,但法令为其额外设定的注册条件,如草药在欧盟至少药用15年历史要求、适应症限制、给药途径限制等,对非欧洲本土来源的中药产品而言仍面临诸多挑战.鉴于"欧盟草药专论"的评价与草药药品简化注册中安全性和有效性的审评标准基本一致,首次从欧盟草药专论的角度,跟踪欧盟草药专论最新评价进展,对影响欧盟草药专论建立的关键因素以及中药产品简化注册过程中的关键问题进行深入分析,并提出建议与对策,以期为中药产品欧盟注册提供一定指导和参考.     

超声雾化吸入在小儿支气管肺炎中的治疗体会

目的探讨超声雾化吸入在小儿支气管肺炎中的应用疗效。方法回顾分析我院94例患儿的临床资料。结果治疗组68例中显效484例,有效16例,无效4例,总有效率为94．11％;对照组显效28例,有效17例,无效27例,总有效率为69．64％。治疗组总有效率明显高于对照组。结论采用布地奈德和氨溴索雾化吸入治疗小儿支气管肺炎,能迅速缓解、改善呼吸道症状,缩短病程,具有局部药物浓度高,吸入时间短,不良反应少,疗效确切患儿及家长容易接受等优点,值得临床推广使用。     

去甲斑蝥素对G422脑胶质瘤抑制作用的体内研究

目的:研究去甲斑蝥素(NCTD)体内对脑胶质瘤G422细胞的抑制作用。方法:建立G422细胞小鼠移植瘤模型,将荷瘤小鼠随机分为模型组、CTX阳性对照组及NCTD高、中、低剂量组(100、50、25 mg.kg-1),每组10只,另设10只为正常对照组,正常对照组每日给生理盐水灌胃,CTX和NCTD组采用腹腔注射方式给药,10 d后双抗体夹心ABC-ELISA法测sIL-2R的含量;酶联免疫ELISA法测IFN-γ含量;剥瘤,计算抑瘤率;剥瘤的同时取脾脏,计算脾脏指数;MTT法检测NCTD对荷瘤小鼠脾脏T、B淋巴细胞增殖的影响。结果:NCTD可降低荷瘤小鼠血清sIL-2R含量,提高IFN-γ含量,抑制G422细胞小鼠移植瘤的生长;对脾脏指数影响较少,可促进荷瘤小鼠的T、B淋巴细胞增殖。结论:NCTD体内外可抑制G422细胞生长,并具有免疫调节作用。     

圆锥角膜发病的力学因素及其机制

圆锥角膜是一种以角膜进行性变薄前突为特征的角膜扩张性疾病。其发病机制尚不清楚。体外实验表明力学刺激可能通过升高氧化应激水平和炎症因子浓度而损伤角膜基质细胞,造成角膜细胞外基质降解等一系列变化。大量临床研究证实揉眼、由睡姿引起的眼球压迫等力学因素可能在圆锥角膜发生发展的过程中起重要作用。它们可能通过增加泪液炎症因子水平、造成眼压变化、改变角膜生物力学性能以及机械摩擦直接损伤角膜组织、升高角膜上皮温度等机制对角膜造成影响。本文就力学因素对角膜基质细胞、角膜组织的影响及其在圆锥角膜发病机制中可能的作用进行阐述,以期为预防和管理圆锥角膜提供参考。     

Prevalence and risk factors for postinfectious cough in discharged patients with coronavirus disease 2019 (COVID-19)

BackgroundCough is one of the most common symptoms of coronavirus disease 2019 (COVID-19). However, the prevalence of persistent cough in recovered patients with COVID-19 during a longer follow-up remained unknown. This study aims to investigate the prevalence, and risk factors for postinfectious cough in COVID-19 patients after discharge.MethodsWe conducted a follow-up study for 129 discharged patients with laboratory-confirmed COVID-19 in two large hospitals located in Hubei Province, China from January 2020 to December 2020. Baseline demographics, comorbidities and smoking history were extracted from the medical record. Current symptoms and severity were recorded by a uniform questionnaire. Spirometry, diffuse function and chest computed tomography (CT) were performed on part of patients who were able to return to the outpatient department at follow-up.ResultsThe median (interquartile range) follow-up time was 8.1 (7.9–8.5) months after discharge. The mean (standard deviation) age was 51.5 (14.9) years and 57 (44.2%) were male. A total of 27 (20.9%) patients had postinfectious cough (>3 weeks), 6 patients (4.7%) had persistent cough by the end of follow-up, including 3 patients with previous chronic respiratory diseases or current smoking. Other symptoms included dyspnea (6, 4.7%), sputum (4, 3.1%), fatigue (4, 3.1%), and anorexia (4, 3.1%) by the end of follow-up. Thirty-six of 41 (87.8%) patients showed impaired lung function or diffuse function, and 39 of 50 (78.0%) patients showed abnormal CT imaging. Patients with postinfectious cough demonstrated more severe and more frequent cough during hospitalization (P<0.001), and more chronic respiratory diseases (P=0.01). In multivariate logistic regression analysis, digestive symptoms during hospitalization [odds ratio (OR) 2.95, 95% confidence interval (CI): 1.10–7.92] and current smoking (OR 6.95, 95% CI: 1.46–33.14) were significantly associated with postinfectious cough of COVID-19.ConclusionsA small part of patients developed postinfectious cough after recovery from COVID-19, few patients developed chronic cough in spite of a higher proportion of impaired lung function and abnormal lung CT image. Current smoking and digestive symptoms during hospitalization were risk factors for postinfectious cough in COVID-19.     

PdPbAg alloy NPs immobilized on reduced graphene oxide/In2O3 composites as highly active electrocatalysts for direct ethylene glycol fuel cells

rGO-modified indium oxide (In₂O₃) anchored PdPbAg nanoalloy composites (PdPbAg@rGO/In₂O₃) were prepared by a facile hydrothermal, annealing and reduction method. Electrochemical tests showed that the as-prepared trimetallic catalyst exhibited excellent electrocatalytic activity and high resistance to CO poisoning compared with commercial Pd/C, mono-Pd and different bimetallic catalysts. Specifically, PdPbAg@rGO/In₂O₃ has the highest forward peak current density of 213.89 mA cm⁻², which is 7.89 times that of Pd/C (27.07 mA cm⁻²). After 3600 s chronoamperometry (CA) test, the retained current density of PdPbAg@rGO/In₂O₃ reaches 78.15% of the initial value. Its excellent electrocatalytic oxidation performance is attributed to the support with large specific surface area and the strong synergistic effect of PdPbAg nanoalloys, which provide a large number of interfaces and achievable reactive sites. In addition, the introduction of rGO into the In₂O₃ matrix contributes to its excellent electron transfer and large specific surface area, which is beneficial to improving the catalytic ability of the catalyst. The study of this novel composite material provides a conceptual and applicable route for the development of advanced high electrochemical performance Pd-based electrocatalysts for direct ethylene glycol fuel cells.

rGO-modified indium oxide (In₂O₃) anchored PdPbAg nanoalloy composites (PdPbAg@rGO/In₂O₃) were prepared by a facile hydrothermal, annealing and reduction method.     

Effectiveness of therapeutic hypothermia for mild neonatal encephalopathy: A protocol for systematic review and meta-analysis

Background:Neonates with moderate to severe encephalopathy benefit significantly from therapeutic hypothermia, with reduced risk of death or disability. However, the need for therapeutic hypothermia for mild neonatal encephalopathy (NE) remains unclear. Therefore, we conducted a protocol for systematic review and meta-analysis to provide evidence supporting therapeutic hypothermia for term or near term neonates with mild NE, including findings of recent long-term outcome studies, as well as novel adjunctive therapies to augment neurodevelopmental outcomes for neonates with NE who receive therapeutic hypothermia.Methods:Two independent researchers performed a systematic literature search in different electronic databases including PubMed, the Cochrane Center Controlled Trials Register, EMBASE, Medline, Ovid, Chinese National Knowledge Infrastructure, Chinese Biomedical Literature Database, and Wanfang Database without any restrictions of languages and date. Two reviewers will screen the records and include quality studies according to inclusion criteria independently. Two reviewers will assess the risk of bias of the included studies by the “Risk of Bias Assessment Tool” of the Cochrane Handbook for randomized controlled trials. Statistical analysis will be performed with Review Manager software 5.3.Results:A synthesis of current evidence of therapeutic hypothermia for treating mild NE will be provided in this protocol.Conclusion:The results of this study will provide a theoretical basis for the clinical use of therapeutic hypothermia in mild NE.     

A comparative study of the efficacy and safety of high-flow nasal cannula and nasal continuous positive airway pressure in neonatal respiratory distress syndrome: A protocol for systematic review and meta-analysis

Background:When it comes to preterm newborns, respiratory distress syndrome (RDS) is the most frequent respiratory condition. Despite the fact that it is well acknowledged that preterm delivery plays a significant role, the causes of lung damage are still not completely understood. In newborns with extremely low birth weight and neonatal RDS, nasal continuous positive airway pressure has been suggested as the first respiratory assistance for spontaneous breathing. In the current research, we aim to carry out a meta-analysis to assess the effectiveness and safety of high-flow nasal cannula (HFNC) and non-invasive continuous positive airway pressure (nCPAP) in patients with neonatal respiratory distress syndrome (NRDS).Methods:We intend to search the following databases: PubMed, EMBASE, Cochrane Library, Wanfang database, China National Knowledge Infrastructure (CNKI), and Google Scholar, starting from their initial publication until February 2022, to identify randomized controlled trials comparing HFNC to nCPAP in patients with NRDS. The suitable papers will be chosen by 2 writers who will work independently of one another. Using the Cochrane updated technique for risk of bias, each included article will be subjected to an independent data extraction process by the 2 writers who will then independently evaluate the risk of bias. Consequently, a third author will be asked to address any discrepancies that may arise between the writers. It will be necessary to pool the data and do a meta-analysis with the help of the RevMan 5.3 software.Results:In this study, the effectiveness and safety of HFNC will be compared with those of nCPAP in patients with NRDS.Conclusion:If the results of this research are confirmed, they may serve as a summary of the most recent data for non-invasive respiratory assistance in NRDS.Ethics and dissemination:The study will require ethical approval.Registration number:DOI 10.17605/OSF.IO/BKSQ5